Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
20 sept. 2022 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
13 sept. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention Study is being conducted in...
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
06 sept. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
09 août 2022 17h16 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
27 juil. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review...
Cidara Therapeutics to Host Research and Development Day
27 juin 2022 08h00 HE
|
Cidara Therapeutics, Inc.
Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th at 10 AM ET SAN DIEGO, June 27, 2022 ...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
11 mai 2022 16h13 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
14 avr. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data...
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
31 mars 2022 08h00 HE
|
Cidara Therapeutics, Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
07 mars 2022 17h41 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...